 |
|
|
| |
Sustained 12 Week Off Treatment Antiviral Efficacy of
ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide
(ASPIN), Combined With Tenofovir Disoproxil Fumarate in Chronic
Hepatitis B Patients, a Phase 2a Clinical Trial
|
| |
| |
EASL 2022 June 22-26 London
Myreen Tomas,1 Alina Jucov,2,3 Igor Anastasiy,4 Rebeca Melara,5 Lauren Ogilvie,1 Karen Fusaro,1 Katherine Squires,1 Douglas Mayers1
1Antios Therapeutics, Doylestown, NJ, USA; 2ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chisinau, Republic of Moldova; 3Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; 4ARENSIA Exploratory Medicine, Kiev, Ukraine; 5Altasciences, Montreal, Quebec, Canada
|
| |
|
|
|
|
|
